11th European Breast Cancer Conference (EBCC 2018)

Breast cancer patients do better without drug holiday

Pearl Toh, 20190508190010

Continuous chemotherapy confers better survival and quality of life than intermittent scheduling in patients with advanced breast cancer, according to the Stop&Go study presented at EBCC 2019.

Breast cancer likely aggressive in young women

Pearl Toh, 20190507190010

Breast cancer in young women tends to be aggressive, according to a study presented at the ESMO Breast Cancer Congress (EBCC) 2019 in Berlin, Germany.

Improved breast cancer-specific survival after double mastectomy in BRCA1 carriers

Roshini Claire Anthony, 20180507140300

Undergoing a bilateral risk-reducing mastectomy (BRRM) appears to improve breast cancer-specific survival (BCSS) and overall survival (OS) in healthy women who are carriers of the BRCA1 mutation, according to a study from The Netherlands. Conversely, women carrying the BRCA2 mutation had similar BCSS regardless of whether they underwent BRRM or surveillance.

Neoadjuvant drug therapy reduces need for mastectomy in HER2-positive breast cancer

Roshini Claire Anthony, 20180502140300

Neoadjuvant chemotherapy plus targeted anti-HER2 therapy may reduce the need for mastectomy and lymph node removal in women with HER2-positive breast cancer, according to a study from Spain that was presented at EBCC 2018.

Netupitant-palonosetron combo + dexamethasone may prevent chemo-induced nausea, vomiting

Audrey Abella, 20180502110000

A single administration of the fixed-dose combination consisting of netupitant plus palonosetron (NEPA) in addition to dexamethasone may be an effective strategy for preventing chemotherapy-induced nausea and vomiting (CINV) among breast cancer patients receiving combination chemotherapy consisting of anthracycline and cyclophosphamide (AC), according to results from the GIM15-NEPA* trial presented at EBCC 2018.

Ribociclib boosts PFS in HR+, HER2- breast cancer

Audrey Abella, 20180502073823

The addition of the selective CDK*4/6 inhibitor ribociclib to a regimen consisting of tamoxifen or a non-steroidal aromatase inhibitor (NSAI) and goserelin prolonged progression-free survival (PFS) and generated a higher objective tumour response rate in pre- or perimenopausal women with HR-positive, HER2-negative advanced breast cancer, according to additional results from the MONALEESA-7** trial presented at EBCC 2018.

Fewer adverse events with reduced dose, partial radiation for low-risk breast cancer

Roshini Claire Anthony, 20180430141200

Women with invasive breast cancer who received hypofractionated intensity modulated radiotherapy (IMRT) at a reduced dose or to only the tumour site (partial radiation) were less likely to report adverse events (AEs) than those who received standard dose IMRT to the whole breast, according to findings of the phase III, UK-based IMPORT LOW* trial.

Local DCIS recurrence low in post-menopausal, ER+ women

Roshini Claire Anthony, 20180424140300

Post-menopausal women diagnosed with oestrogen receptor (ER)-positive ductal carcinoma in situ (DCIS) who undergo breast-conserving surgery followed by whole breast radiotherapy have a reduced risk of developing local recurrence, according to a study from Italy.